Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

Similar articles for PubMed (Select 16709016)

1.

The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.

Shimamura T, Husain SR, Puri RK.

Neurosurg Focus. 2006 Apr 15;20(4):E11. Review.

PMID:
16709016
2.

Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.

Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK.

Technol Cancer Res Treat. 2006 Jun;5(3):239-50. Review.

PMID:
16700620
3.

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.

Husain SR, Puri RK.

J Neurooncol. 2003 Oct;65(1):37-48. Review.

PMID:
14649884
4.

Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.

Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, Husain SR, Joshi BH, Pedain C, Puri RK.

Neurosurg Focus. 2006 Apr 15;20(4):E15.

PMID:
16709020
5.

Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.

Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK; Cintredekin Besudotox Intraparenchymal Study Group.

J Clin Oncol. 2007 Mar 1;25(7):837-44.

7.

Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK.

Clin Cancer Res. 2000 Jun;6(6):2157-65.

8.

Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.

Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, Croteau D, Puri RK, Chang SM.

J Neurosurg. 2005 Feb;102(2):267-75.

PMID:
15739554
9.

Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.

Kawakami M, Kawakami K, Puri RK.

J Neurooncol. 2003 Oct;65(1):15-25. Review.

PMID:
14649882
10.

Cintredekin besudotox in treatment of malignant glioma.

Mut M, Sherman JH, Shaffrey ME, Schiff D.

Expert Opin Biol Ther. 2008 Jun;8(6):805-12. doi: 10.1517/14712598.8.6.805 . Review.

PMID:
18476792
11.
12.
13.

Clinical studies with targeted toxins in malignant glioma.

Rainov NG, Söling A.

Rev Recent Clin Trials. 2006 May;1(2):119-31. Review.

PMID:
18473963
14.

Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.

Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK.

Neurosurgery. 2007 Nov;61(5):1031-7; discussion 1037-8.

PMID:
18091279
15.

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK; PRECISE Study Group.

Neuro Oncol. 2010 Aug;12(8):871-81. doi: 10.1093/neuonc/nop054. Epub 2010 Feb 4.

16.

Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.

Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20021-6. doi: 10.1073/pnas.1008261107. Epub 2010 Oct 28.

17.
18.

Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells.

Debinski W, Miner R, Leland P, Obiri NI, Puri RK.

J Biol Chem. 1996 Sep 13;271(37):22428-33.

20.

Novel anti-brain tumor cytotoxins specific for cancer cells.

Debinski W, Gibo DM, Obiri NI, Kealiher A, Puri RK.

Nat Biotechnol. 1998 May;16(5):449-53.

PMID:
9592393
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk